BFM
PACB icon

Boothbay Fund Management’s Pacific Biosciences PACB Stock Holding History

Boothbay Fund Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,608
Closed -$43.2K – 1684
2024
Q4 		$43.2K Buy
+23,608
New +$46.1K ﹤0.01% 1370
2022
Q4 		– Sell
-14,283
Closed -$83K – 2338
2022
Q3 		$83K Buy
+14,283
New +$81.9K ﹤0.01% 2071
2020
Q2 		– Sell
-19,800
Closed -$61K – 1077
2020
Q1 		$61K Buy
+19,800
New +$81.1K 0.01% 772
2016
Q3 		– Sell
-13,080
Closed -$92K – 782
2016
Q2 		$92K Buy
+13,080
New +$119K 0.04% 459

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's PACB Position: Q1 2025 in Review

Boothbay Fund Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 23,608 shares — an estimated $43.2K sold.

Boothbay Fund Management first reported a position in PACB in Q2 2016 and held it in 4 quarters. The position peaked at $92K in Q2 2016. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Boothbay Fund Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 23,608 Pacific Biosciences shares in Q1 2025, an estimated $43.2K.
  • Boothbay Fund Management first reported a position in Pacific Biosciences in Q2 2016 and held it in 4 quarters.
  • Boothbay Fund Management's Pacific Biosciences position peaked at $92K in Q2 2016.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.